Abpro Holdings, Inc. (ABPO) stock
ABPOOTCBiological Products, (No Diagnostic Substances)Fiscal year ends December 31Also trades as ABPWW
$0.41+0.00 (+0.11%)
Close on Oct 19, 2026Market cap $2.41MP/E –Yield –
Abpro r&d expenses
Research and development expenses are spending on new products and technology.
Abpro's R&D Expenses for the twelve months ending Jun 30, 2026 was $373.00K. For fiscal 2025 it was $989.00K, down 66.8% from the year before.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $989.00K | -66.8% |
| FY2024 | Dec 31, 2024 | $2.98M | -30.1% |
| FY2023 | Dec 31, 2023 | $4.27M | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $9.00K | -97.1% |
| Q1 FY2026 | Mar 31, 2026 | $13.00K | -96.0% |
| Q4 FY2025 | Dec 31, 2025 | $108.00K | -86.9% |
| Q3 FY2025 | Sep 30, 2025 | $243.00K | -75.7% |
| Q2 FY2025 | Jun 30, 2025 | $313.00K | – |
| Q1 FY2025 | Mar 31, 2025 | $325.00K | – |
| Q2 FY2024 | Jun 30, 2024 | $827.00K | – |
| Q1 FY2024 | Mar 31, 2024 | $1.00M | – |
See a number that looks wrong?